Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

February’s top stories: Merck’s Phase III HIV-1 trial results, NIH’s Phase I AGS-v vaccine trial

Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v to prevent mosquito-transmitted diseases. Drugdevelopment-technology.com wraps up the key headlines from February.

Go Top